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Background: To optimize treatment regimens, we assessed human immunodeficiency virus (HIV) diversity and the
prevalence of transmitted drug resistance (TDR) among men who have sex with men (MSM) in Anhui province,
China.
Methods: A total of 139 MSM who were newly diagnosed and antiretroviral treatment-naive were enrolled in Anhui
in 2011. A partial pol fragment was amplified and sequenced, and HIV subtypes were determined by phylogenetic
analyses. Surveillance/transmitted drug resistance mutations (SDRMs) were identified according to the 2009 World
Health Organization (WHO) list.
Results: A total of 133 (95.7%) samples were successfully amplified and sequenced. Based on phylogenetic analyses
of the pol fragment, CRF01_AE accounted for 55.6% (74/133) of the infections, followed by CRF07_BC with 32.3%
(43/133), B with 5.3% (7/133), and unique recombinant forms with 6.8% (9/133). A total of 3.0% (4/133) of the
subjects were found to harbor HIV variants with SDRMs, including 1.5% with NRTI-related mutations and 1.5% with
NNRTI-related mutations. PI-related mutations were absent. The SDRMs included L210W (1.5%), Y181C (0.8%), and
G190A (0.8%).
Conclusions: In Anhui, CRF01_AE strains contributed to most of the HIV infections among MSM, and the
prevalence of TDR was relatively low in this population. Further studies should be performed to evaluate the trend
of TDR among MSM in Anhui and to inform first-line antiretroviral treatment.
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Globally, 34.0 million people were living with HIV by
the end of 2011. An estimated 0.8% of adults 15–49
years of age worldwide are currently living with HIV-1
[1]. Studies suggest an increasing HIV-1 prevalence
among men who have sex with men (MSM), and some
evidence indicates that the global prevalence of HIV-1
infection among MSM has increased from 2010 to 2012
[2,3]. The HIV-1 epidemic in China has also increased.
By the end of 2011, there were 780,000 people in China
infected with HIV-1, with a national prevalence rate of
0.058%. Of the infected individuals, 63.9% were infected
through sexual transmission, including 46.5% through
heterosexual transmission and 17.4% through homosex-
ual transmission [4]. Among the estimated 48,000 newly* Correspondence: sub@ahcdc.com.cn
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unless otherwise stated.diagnosed cases in 2011, heterosexual transmission
accounted for 52.2%, homosexual transmission for
29.4%, and injection drug users (IDUs) for 18.0% of the
cases [4].
Anhui province, located in south-eastern China, neigh-
bors Henan province and was defined as an HIV-1 epi-
demic focus where most infections were caused by
former commercial blood donation [5]. However, newly
diagnosed infections have rapidly increased through
homosexual transmission among MSM in recent years
[4]. To date, 768 MSM have been reported to be infected
with HIV in Anhui province.
According to the national guidelines for antiretroviral
(ARV) treatment in China, HIV-1-infected persons
should receive antiretroviral therapy (ART) when their
CD4 counts are less than 350 cells/μL. Extensive use of
ARV drugs has led to the increasing transmission of
HIV variants with drug resistance mutations that can bed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[6-9], and gives rise to a reduction in efficacy of first-line
ART [10]. From the beginning of national scale-up of
combined antiretroviral therapy in China, many HIV
drug resistance surveys have been conducted, and viral
mutations conferring resistance to protease inhibitors
(PIs) and/or reverse transcriptase inhibitors (RTIs) has
been found in both ARV-treated patients and treatment-
naive patients [11-15]. However, little is known about
mutations associated with HIV-1 resistance to PIs and/
or RTIs in newly diagnosed ART-naive MSM in Anhui.
To provide information about the epidemic trends of
HIV and to optimize the treatment strategies in Anhui,
the prevalence of surveillance/transmitted drug resist-
ance mutations (SDRMs) was evaluated in ART-naive
MSM who were newly diagnosed as HIV-infected in
2011.
Materials and Methods
Study population and specimens
A cross-sectional study was conducted among newly di-
agnosed HIV-infected MSM in 15 prefectures of Anhui
in 2011, according to guidelines of the Anhui Center for
Disease Control and Prevention (CDC), which provides
HIV/AIDS treatment and prevention services through
education, quality services, and compassionate care to
those with HIV/AIDS. Our research included the follow-
ing 15 cities: Fuyang, Bozhou, Huaibei, Huainan, Suzhou,
Bengbu, Hefei, Liu’an, Anqing, Huangshan, Xuancheng,
Ma’anshan, Wuhu, Tongling and Chizhou. All newly diag-
nosed MSM with HIV were enrolled, except for MSM
with known exposure to ARV drugs. All subjects were in-
cluded anonymously and provided written informed con-
sent. Demographic data were collected through direct
interview using a standardized questionnaire prior to sam-
ple donation. Blood samples were collected from 139 indi-
viduals. Plasma was isolated within 6 hours of sampling
and stored at −80°C until HIV drug resistance genotyping.
The study was reviewed and approved by the local Ethical
Review Committee of the Anhui CDC.
RT-PCR and nested PCR amplification
A partial pol fragment was amplified and sequenced with
an in-house protocol, as previously described [16,17].
Briefly, viral RNA was extracted from plasma using a
QIAamp Viral RNA Mini kit (Qiagen, Valencia, CA,
USA). HIV-1 cDNA was obtained and amplified using a
one step RT-PCR kit (TaKaRa Biotechnology Co, Dalian,
China) with primers RT21 (5’-CTG TAT TTC TGC
TAT TAA GTC TTT TGA TGG G-3’, 3509–3539 nt,
HBX2) and MAW26 (5’-TTG GAA ATG TGG AAA
GGA AGG AC-3’, 2027–2050 nt, HBX2). The RT-PCR
product was then used as a template and the nested
PCR primers PRO-1 (5’-CAG AGC CAA CAG CCCCAC CA-3’, 2147–2166 nt, HBX2) and RT4R (5’-CTT
CTG TAT ATC ATT GAC AGT CCA GCT-3’, 3299–
3327 nt, HBX2) were used to amplify a pol fragment that
included the whole protease (PR) and partial reverse
transcriptase (1–250 amino acids, RT). The PCR prod-
ucts were purified by a gel extraction kit (Qiagen, Valencia,
CA) and bidirectly sequenced using BigDye termin-
ator sequencing technology (Applied Biosystems, Foster
City, CA, USA) on an Applied Biosystems 3730 Se-
quencer [18,19].
HIV-1 subtyping
The sequences of the pol fragment were aligned with
reference sequences from the Los Alamos database using
the BioEdit 7.0 software. HIV-1 subtype was determined
by phylogenetic analyses using the neighbor-joining
method [20]. For specimens of unknown HIV-1 subtype,
bootscanning analyses were performed to screen for a
recombination breakpoint using Simplot 3.5 software.
Drug resistance genotyping of HIV-1 isolates
The pol sequences were compared with consensus B se-
quence in the Stanford HIV Drug Resistance Database
(HIVdb; http://hivdb.stanford.edu), and surveillance/trans-
mitted HIV-1 drug resistance mutations (SDRMs) were
identified according to the 2009 World Health Organiza-
tion (WHO) list [21]. The levels of drug resistance were an-
alyzed with the HIVdb algorithm.
Statistical analysis
Median (standard deviation, SD), range and frequencies
(%) were used to describe patients’ characteristics. The
frequency of SDRMs was also calculated. Statistical ana-




The median age of the 139 newly diagnosed HIV-1-
infected MSM was 31.6 years (range 18–68), and half
(48.2%) of them were youths (between 18–29 years old)
(Table 1). A majority of subjects were of Han ethnicity,
65.5% were single, and 20.1% were married. Most partic-
ipants (93.6%) had completed middle school or higher
education. The main occupations were business service
personnel (28.1%), officer/worker (19.4%), jobseeker/
housekeeper (15.1%), and farmer (13.6%). A quarter of
the subjects had sexually transmitted diseases in addition
to HIV, and 80.8% of the individuals had CD4 counts
equal to or above 350 cells/μl (Table 1).
HIV-1 subtypes and recombinant strains
A total of 133 (95.7%) specimens were successfully amp-
lified and sequenced. According to a phylogenetic tree
Table 1 Characteristics of 139 HIV-1-infected
treatment-naive MSM












Married and having spouse 28 20.1
Unknown 5 3.6
Highest education achieved
Elementary school 9 6.4
Middle school 45 32.4
High school 37 26.6
College and above 48 34.5
Occupation
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using the neighbor-joining method, two circulating re-
combinant forms (CRF) and one subtype were identified.
The CRF01_AE strain was identified in 74 (55.6%) per-
sons, CRF07_BC in 43 (32.3%) individuals, and subtype
B in seven (5.3%) subjects (Table 2). Nine unique recom-
binant forms (URF) were determined according to
phylogenetic inference and bootscanning analyses, in-
cluding six CRF01_AE/B, two CRF01_AE/CRF07_BC,and one CRF01_AE/CRF01_B/CRF07_BC recombinant
strain [20]. In the 35 specimens obtained from six north-
ern cities (Fuyang, Bozhou, Huaibei, Huainan, Suzhou
and Bengbu), CRF01_AE was found to be the predomin-
ant subtype (74.3%, 26/35). The dominance of CRF01_AE
was also observed among MSM residing in the cities along
the Yangtze River, such as Chizhou (100%, 1/1), Ma’anshan
(66.7%, 4/6), Wuhu (58.8%, 10/17) and Tongling (50%, 2/
4). It was also found in the central cities of Hefei (52.9%,
18/34) and Liu’an (50%, 1/2). In contrast to these high per-
centages of CRF01_AE, CRF07_BC was found to consti-
tute the majority of infections in Bozhou (75%, 3/4), a
northern city, and Anqing (64.3%, 9/14), a central city.
Identification and interpretation of surveillance/
transmitted drug resistance mutations
Four cases were found have SDMRs: two from Anqing,
one from Ma’anshan and one from Xuancheng. The rate
of transmitted drug resistance (TDR) was 3.0% (4/133) for
all ART drug classes, including nucleoside reverse tran-
scriptase inhibitor (NRTIs)-related resistance in 1.5% (2/
133) of the individuals, non-nucleoside reverse transcript-
ase inhibitor (NNRTIs)-related in 1.5% (2/133) of the sub-
jects, and no PI-related resistance. The sole NRTI-related
SDRM was L210W, detected in two individuals infected
with CRF01_AE strains (from Anqing and Ma’anshan).
The two NNRTI-related SDRMs were Y181C and
G190A, found in persons infected with CRF01_AE (from
Xuancheng) and B (from Anqing) strains, respectively
(Table 3). L210W confers a low level of resistance to zi-
dovudine (AZT) and stavudine (D4T). Y181C confers a
high level of resistance to nevirapine (NVP) and an
intermediate level of resistance to efavirenz (EFV), etra-
virine (ETR) and rilpivirine (RPV). G190A confers a high
level of resistance to NVP and an intermediate level of
resistance to EFV. However, two other mutations which
confer resistance to RTIs, A98G and V79D, were not in-
cluded in the 2009 WHO SDRM list but were identified
here. A98G confers a low level of resistance to EFV and
NVP, and while V179D in a URF strain confers a low
level of resistance against EFV and an intermediate level
of resistance against NVP, V179D in CRF01_AE does not
affect resistance to any RT drugs. T69A/N/S, V179E and
P236L were polymorphism mutations against RTIs.
Genotyping analysis revealed that none of the speci-
mens had SDRMs against PIs. However, some accessory
mutations that did not affect susceptibility to ARV drugs
were found in the protease gene, including L10I/L/V
(3.0%; 4/133), V11I/V (3.0%; 4/133), L33F (2.3%; 3/133),
and A71A/V/T (12.8%; 17/133).
Discussion
Our findings showed that CRF01_AE accounted for the
majority (55.6%) of HIV-1-infections in MSM of Anhui
Table 2 Distribution of HIV-1 subtypes among newly diagnosed MSM (n = 133)
Region City Cases (n) HIV-1 subtypes (n)
CRF01_AE CRF07_BC B Other
Northern Fuyang 5 3 0 1 1
Bozhou 4 1 3 0 0
Huaibei 2 2 0 0 0
Huainan 12 10 1 1 0
Suzhou 3 3 0 0 0
Bengbu 9 7 0 0 2
Central Hefei 34 18 13 1 2
Liu’an 2 1 1 0 0
Anqing 14 4 9 1 0
Southern Ma’anshan 6 4 2 0 0
Wuhu 17 10 3 1 3
Tongling 4 2 2 0 0
Chizhou 1 1 0 0 0
Xuancheng 13 5 6 1 1
Huangshan 7 3 3 1 0
Total (%) 133 (100) 74 (55.6) 43 (32.3) 7 (5.3) 9 (6.8)
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survey of HIV-1 molecular epidemiology in 2006, which
reported that CRF07_BC (35.5%), CRF01_AE (27.6%),
CRF08_BC (20.1%), and subtype B' (9.6%) were the four
predominant HIV-1 strains in China [22]. Furthermore,
CRF01_AE has replaced subtype B as the most common
subtype among MSM [16,22]. The dominance of
CRF01_AE was observed among MSM in coastal cities
and provinces, such as Tianjin (88.9%), Jiangsu (70%),
Shandong (77.8%), and Zhejiang (100%), in one province
of central China, Shanxi (84.6%), and in one province of
western China, Gansu (50%) [23].
In this study, a high proportion of MSM (30.9%) were
married or divorced, raising concerns about the risk of
acquiring HIV-1 from or transmitting HIV-1 to their
sexual partners. Various forms of HIV transmission, in-
cluding both homosexual and heterosexual behavior,
likely exist among MSM of Liaoning province [24].
Therefore, further study should be carried out to deter-
mine which subtypes of HIV-1 predominantly infect the
heterosexuals and IDUs.Table 3 Frequency of surveillance/transmitted drug
resistance mutations
Drug class Mutant sites Number Prevalence (%)




Total 4 3.00We focused on HIV-1-infected treatment-naive MSM
in Anhui province, and found that the overall TDR rate
was 3.0%, slightly lower than the national level and
Liaoning province [23,24]. The first nationwide survey of
TDR in HIV-1-infected treatment-naive individuals was
conducted in 2005, and the national TDR rate was reported
to be 3.8% [4]. In 2011, the overall TDR rate was 4.9%
among HIV-1-infected treatment-naive MSM in 19
Chinese provinces/cities (Anhui province was not included)
[23]. According to an investigation in Liaoning province,
4.5% of ART-naive MSM had drug-resistant strains [24].
We report that 1.5% of samples were resistant to
NRTIs, 1.5% of samples were resistant to NNRTIs, and
none were resistant to PIs. Specific mutations included
L210W, Y181C, and G190A, which confers different
levels of drugs resistance. However, we detected many
minor mutations which could compensate for the reduced
fitness of resistant mutants, even though the minor muta-
tions have not previously been associated with decreased
in vitro susceptibility. Other commonly observed muta-
tions were T69A/N/S, V179E, L10I/L/V, V11I/V, L33F,
and A71A/T/V; none of these mutations is known to con-
fer drug resistance to NRTIs, NNRTIs, or PIs.
Specific polymorphisms may occur in particular sub-
types. For example, L10V, V11I/V, L33F, T69A/N/S, and
P236L were present only in individuals with CRF01_AE
strains. These mutations do not affect the susceptibility
to ARV drugs. However, they might influence the emer-
gence of drug-resistant viruses by modifying drug sus-
ceptibility and/or virus replication [25]. The present
study found that substitutions of A71T/V and L10I often
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studies reporting that substitutions of A71T/V often ap-
peared in B viruses, whereas L10I was frequently discov-
ered in CRF01_AE viruses [26]. A98G and V179E were
excluded from the WHO list of SDRMs because of high
occurrence in viruses from treatment-naive individuals.
A98G has been shown to confer low-level resistance
against EFV and NVP, and V179D in CRF01_AE/
CRF07_BC recombinant viruses has been shown to confer
low-level resistance against EFV and intermediate level re-
sistance against NVP, while V179D in CRF01_AE viruses
does not affect resistance to any RT drugs (data not pub-
lished). This phenomenon is worthy of further study.
Our data represent only TDR in HIV-1-infected
treatment-naive MSM in Anhui province; therefore, the
results may not be representative of other areas. Neverthe-
less, these data warn us that HIV transmitted-drug-
resistant isolates may be prevalent among HIV-1-infected
treatment-naive MSM, which will no doubt compromise
the success of future ART in these patients.
There were several limitations in our study. First,
although all the subjects were newly diagnosed as HIV-
infected, the date of their infections was not known. How-
ever, it is suggested that a substantial proportion of the
subjects were infected recently, because more than half of
the individuals had CD4 counts of ≥350 cells/μl, and al-
most half were between 18–29 years old. Second, the
prevalence of TDR might be underestimated, because
some mutations may have disappeared over time due to
lack of replicative fitness. However, some NNRTI-related
mutations, such as K103N, can persist for a long period of
time [27,28].
Conclusions
This study is the first to describe HIV diversity and TDR
prevalence in ART-naive, HIV-1-infected MSM in Anhui
province. CRF01_AE was found to be a major subtype,
TDR prevalence was relatively low, and most TDR cases
were associated with RTIs. These findings provide base-
line information of HIV-1 transmitted-drug-resistant
mutations, which has implications for HIV/AIDS pre-
vention and treatment programs among MSM patients
in China. Further studies of TDR are necessary to deter-
mine the trend of TDR in Anhui province and to
optimize treatment regimens in the future.
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